Enliven Therapeutics secures $400 million in strategic investment
Summary
Enliven Therapeutics has secured $400 million in strategic investment. The company develops cancer therapies and focuses on hard-to-solve problems such as drug resistance, target binding, and brain metastasis escape. It plans to use the capital to advance next-generation covalent inhibitors for EGFR and KRAS mutations and to prepare for a Phase II trial. The funding will also support team growth and additional translational medicine research. Multiple multinational pharmaceutical companies and specialist life sciences funds participated in the round.
Funding
Amount
$400.0M
Total raised
Date
June 17, 2026
Announcement date
Investors
-
Lead investors
Company
enliventherapeutics.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected